Results 91 to 100 of about 4,485 (161)

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

Vascular Health and Risk Management, 2010
Katarina RaslovaMetabolic Center Ltd and Slovak Medical University, Bratislava, Slovak RepublicAbstract: Basal insulin analogs are used to minimize unpredictable processes of NPH insulin.
Katarina Raslova
doaj  

The economic prognosis of the new analog of insulin glargine usage in diabetes mellitus type 2

Качественная клиническая практика, 2018
Modelling has been performed for evaluation of economic perspectives of new insulin glargine 300 IU/ml usage for diabetes mellitus type 2 (DM2) control based on literature analysis of non-direct comparison with insulin detemir.
D. Yu. Belousov, E. V. Afanasyeva
doaj  

Clinical Experience of Insulin Detemir in Turkey: Efficacy and Safety Data From the PREDICTIVE™ Study

Endocrinology Research and Practice, 2008
Objective: To assess outcomes in Turkish type 1 and 2 diabetic patients given insulin detemir in the multinational PREDICTIVE™ study. Materials and Methods: PREDICTIVE™ was a large, open-label, prospective, observational study examining the efficacy and
Mustafa Yenigün, Gonca Oruk, Akın Dayan, Gaye Akoz, Sevil Emek   +4 more
doaj  

Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials. [PDF]

Diabetes Obes Metab
Amaral R, Costa B, Penedones A, Mendes D, Alves C.   +4 more
europepmc   +1 more source

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues. [PDF]

Front Endocrinol (Lausanne)
Zhong L, Cao W, Liu X, Wen T, Yan J.
europepmc   +1 more source

Insulin Detemir Offers Improved Glycemic Control Compared with NPH Insulin in People with Type 1 Diabetes: A randomized clinical trial

OBJECTIVE - ]Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations.
Home P, Landin-Olsson M, Draeger E, Hylleberg B, Abrams P, Hanaire-Broutin H, Lang H, Russell-Jones D, Bartley P, Heeg J-E   +9 more
core   +2 more sources

Management of Nocturnal Hypoglycaemia in a Patient with Type 2 Diabetes: The Role of Community Pharmacy. [PDF]

Farm Comunitarios
Nadal Domingo S, Mir Palomo S, Domingo Tortajada D.   +2 more
europepmc   +1 more source

Effects of Different Exogenous Insulin Analog Treatments on the Evaluation of Pancreatic Islet Function in Diabetes. [PDF]

J Diabetes Res
Ma YF, Neng QL, Ou Y, Zhou YK.
europepmc   +1 more source

Delayed Hypersensitivity Reaction to Insulin: A Case Report. [PDF]

Cureus
Aharmim M, Lakhal M, Reguig N, El Bourkadi JE.   +3 more
europepmc   +1 more source

Impact of structure and formulation changes on the function of insulin products. [PDF]

Front Endocrinol (Lausanne)
Yang Y, Shahinozzaman M, Shin H, Bupp S, Sourbier C.   +4 more
europepmc   +1 more source